Latest KFF Health News Stories
Millions in US Live in Places Where Doctors Don’t Practice and Telehealth Doesn’t Reach
Nearly 3 million Americans live sicker, shorter lives in the hundreds of rural counties where doctor shortages are the worst and poor internet connections mean little or no access to telehealth services.
Este método, que podría llegar a tener gran utilidad en la era de los teléfonos inteligentes, es una aplicación que permite efectuar consultas médicas transfronterizas.
Schools Aren’t as Plugged In as They Should Be to Kids’ Diabetes Tech, Parents Say
With continuous glucose monitors, students with Type 1 diabetes no longer have to visit the school nurse for a finger prick. But some parents say it falls to them to keep an eye on blood sugar levels from home or work — even though they may not be able to quickly reach their child when something’s wrong.
Las escuelas no están conectadas como debieran a la tecnología para afrontar la diabetes infantil
En las escuelas, los maestros están atentos a las alarmas de los MCG de los teléfonos de los alumnos. Sin embargo, muchos dicen que no hay garantía de que un maestro pueda escucharlas.
Who Gets Obesity Drugs Covered by Insurance? In North Carolina, It Helps If You’re on Medicaid
GLP-1 agonist medications such as Ozempic accounted for 10% of the North Carolina state employee health plan’s prescription drug spending, so the state is no longer covering them for weight loss alone. Still, it did decide to cover them for Medicaid patients’ weight loss. A look inside the state’s coverage calculus.
¿Podrían los nuevos medicamentos para bajar de peso estar disponibles para todos?
Los medicamentos agonistas GLP-1, conocidos por los nombres comerciales Ozempic, Trulicity y Wegovy, han demostrado ser efectivos para la pérdida de peso y para el manejo de la diabetes tipo 2.
How Minnesota Figures Into the Presidential Politics of Insulin Prices
Minnesota led the way on insulin affordability, culminating in 2020 when Gov. Tim Walz signed a law going further to cut costs than other state laws. Now, former President Donald Trump and Vice President Kamala Harris are vying for support from people with diabetes.
Harris, alguna vez la voz de Biden sobre el aborto, tendría un enfoque abierto en temas de salud
Mientras los demócratas reconstruyen su candidatura presidencial a pocos meses de las elecciones, se esperaría que, de ser la nueva nominada, Harris adoptase una postura agresiva en apoyo al acceso al aborto y en otros temas controversiales de salud.
Harris, Once Biden’s Voice on Abortion, Would Take an Outspoken Approach to Health
If she grabs the baton from President Joe Biden to become the new presumptive Democratic presidential nominee, Kamala Harris would widely be expected to take an aggressive stance in support of abortion access — hitting former President Donald Trump on an issue that could undermine his chances of victory.
1st Biden-Trump Debate of 2024: What They Got Wrong, and Right
A debate marked by President Joe Biden’s faltering performance featured clashes over insulin costs, inflation, abortion, immigration, and Jan. 6.
Journalists Talk Cost of Weight Loss Drugs and Lack of Obesity Doctors to Manage Their Use
KFF Health News and California Healthline staff made the rounds on national and local media this week to discuss topical stories. Here’s a collection of their appearances.
High Price of Popular Diabetes Drugs Deprives Low-Income People of Effective Treatment
The makers of Ozempic and Mounjaro charge list prices of around $1,000 a month for the diabetes and obesity drugs, and insurers are reluctant to pick up the tab. Often, low-income patients have to resort to less effective treatments.
Personas de bajos ingresos no pueden recibir terapias efectivas contra la diabetes por el alto costo
La escasez de suministros y las barreras que ponen las aseguradoras para obtener esta poderosa clase de medicamentos, llamados agonistas de GLP-1, han dejado a muchas personas que viven con diabetes y obesidad sin los medicamentos que necesitan para mantenerse saludables.
Biden Is Right About $35 Insulin Cap but Exaggerates Prior Costs for Medicare Enrollees
Most Medicare enrollees likely were not paying a monthly average of $400 — as President Joe Biden stated — before the insulin cap took effect. However, because costs and other factors result in widely varying prices, some Medicare enrollees might have paid that much in a given month.
Programas de inteligencia artificial diagnostican retinopatía diabética en minutos
En medio de todo el revuelo en torno a la inteligencia artificial en la atención médica, la tecnología de exámenes de la vista está surgiendo como uno de los primeros casos de uso probados de diagnósticos basados en IA en un entorno clínico.
As AI Eye Exams Prove Their Worth, Lessons for Future Tech Emerge
With artificial intelligence in health care on the rise, eye screenings for diabetic retinopathy are emerging as one of the first proven use cases of AI-based diagnostics in a clinical setting.
An Arm and a Leg: Wait, Is Insulin Cheaper Now?
Did the price of insulin go down? It’s not quite that simple. On this episode of “An Arm and a Leg,” producer Emily Pisacreta explores recent changes to the cost of the diabetes medication.
States Target Health Insurers’ ‘Prior Authorization’ Red Tape
Doctors, patients, and hospitals have railed for years about the prior authorization processes that health insurers use to decide whether they’ll pay for patients’ drugs or medical procedures. The Biden administration announced a crackdown in January, but some state lawmakers are looking to go further.
These Patients Had to Lobby for Correct Diabetes Diagnoses. Was Their Race a Reason?
Adults who develop one autoimmune form of diabetes are often misdiagnosed with Type 2 diabetes. Those wrong diagnoses make it harder to get the appropriate medications and technology to manage their blood sugar. Many Black patients wonder if their race plays a role.
Beyond Insulin: Medi-Cal Expands Patient Access to Diabetes Supplies
California’s Medicaid program is making it easier for people with diabetes to obtain the supplies and equipment they need to manage their blood sugar, partly by relaxing preauthorization requirements that can cause life-threatening delays.
